Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/207222
Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
With the increasing availability of sequencing techniques and new polymerase chain reaction-based methods, data regarding the genomic profile of Waldenström macroglobulinemia (WM) are being continuously analyzed and reproduced. MYD88 and CXCR4 mutations are highly prevalent in all the stages of WM, including the early IgM monoclonal gammopathy of undetermined significance or a more advanced stage, such as smoldering WM. Thus, there is a need to define genotypes before starting either standard treatment regimens or clinical trials. Here, we review the genomic profile of WM and its clinical implications while focusing on recent advances.Copyright © 2023 Elsevier Inc. All rights reserved.
Subject
Subject (English)
Citation
Citation
MORENO FAJARDO, David Fernando and FERNÁNDEZ DE LARREA RODRÍGUEZ, Carlos José. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia. Hematology-Oncology Clinics Of North America. 2023. Vol. 37, num. 4, pags. 659-670. ISSN 0889-8588. [consulted: 12 of August of 2026]. Available at: https://hdl.handle.net/2445/207222